Belrestotug

Phase 3Small molecule

GSK

Belrestotug is one of 109 small molecule programs targeting Neoplasms, Head and Neck. It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoplasms, Head and NeckActive, not recruiting

NeoplasmsActive, not recruiting

Lung Cancer (non-Small Cell)Active, not recruiting

Advanced Solid TumorsActive, not recruiting

Lung CancerActive, not recruiting

Neoplasms, Head and NeckPhase 2

Active, not recruiting

NeoplasmsPhase 1

Active, not recruiting

Lung Cancer (non-Small Cell)Phase 3

Active, not recruiting

Advanced Solid TumorsPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Tecentriq

Roche

Phase 2

11 3

Taxotere

AAvyxa

Phase 2

23 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 5

Braftovi

Pfizer

Phase 2

4 6

Sutent

Pfizer

Phase 2

3 7

Alimta

SShawn Eagle

Phase 2

13 8

Tarceva

OOSI Pharmaceuticals

Phase 2

7 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

7 10

Belrestotug

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04446351

Q1 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05565378

Q3 2027

Phase 3Active, not recruiting

Lung Cancer (non-Small Cell)

NCT06472076

Phase 1Active, not recruiting

Neoplasms

NCT05277051

Q4 2027

Phase 2Active, not recruiting

Neoplasms, Head and Neck

NCT06062420

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04446351·107 enrolled

Lung Cancer1 trial

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05565378·351 enrolled

Non-Small Cell Lung Cancer1 trial

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Completed· GSK logo

GSK·Phase 2·NCT06926673·62 enrolled

Lung Cancer (Non-Small Cell)1 trial

A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)

Active, not recruiting· GSK logo

GSK·Phase 3·NCT06472076·88 enrolled

Neoplasms1 trial

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT05277051·152 enrolled

1 more indication

Neoplasms, Head and Neck1 trial

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06062420·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Belrestotug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belrestotug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belrestotug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Belrestotug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Advanced Solid Tumors1 trial

Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Lung Cancer (Non-Small Cell)1 trial

Neoplasms1 trial

Neoplasms, Head and Neck1 trial

References

Drug Info

Quick Facts

Related News